Home/Pipeline/Schizophrenia Intermediate

Schizophrenia Intermediate

Schizophrenia

Proof of conceptActive

Key Facts

Indication

Schizophrenia

Phase

Proof of concept

Status

Active

Company

OFD Biopharma

About OFD Biopharma

OFD Biopharma, a division of OFD Life Sciences, is a US-based CDMO providing expert lyophilization solutions to stabilize complex pharmaceuticals. The company differentiates itself through its focus on bulk lyophilization and proprietary platforms like LyoLock and LyoPastille, which aim to enhance drug stability, solubility, and bioavailability. It offers end-to-end support from R&D through commercialization, serving clients in oncology, immunology, and other therapeutic areas. As a private service provider, its financial model is based on client contracts and project milestones.

View full company profile

Therapeutic Areas

Oncology Immunology Infectious Disease Gastrointestinal Central Nervous System

Other Schizophrenia Drugs

Drug	Company	Phase	Status
DB103 (Pomaglumetad)	Denovo Biopharma	Phase 2b/3	Active
ZZ6398	Zhongze Therapeutics	Phase 1/2	Active
RBP-7000 (PERSERIS®)	Indivior	Marketed	Commercial
Undisclosed Programs	johnson-and-johnson-innovative-medicine	Pipeline	Active
Schizophrenia Candidate	Teva	Phase 3	Active
Schizophrenia Model Service	NeuroProof	Pre-clinical	Active
LYN-005 (Nortiva)	Lyndra	Phase 3	Active
TerXT	Terran Biosciences	Late-stage (Pre-Phase 3)	Active
Undisclosed Program	Curemark	Preclinical	Active
Schizophrenia	Keltic Pharma Therapeutics	Pre-clinical	Active
AVAT-031	Avata Biosciences	Discovery	Active
Risperidone Implant	Delpor	Phase 1b/2a / Late-stage	Active